Searched for
EMCURE
Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, VedantaIndian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but unce...- PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stakePrivate equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...
- Delhivery elevates six executives to C-suite roles amid expansion pushLogistics firm Delhivery has promoted six senior executives to C-suite positions. These appointments support the company's expansion across...
- Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...
- Stocks in news: Paytm, Bajaj Auto, L&T, Bharti Airtel, Hero MotoCorpMarkets closed lower amid global headwinds and geopolitical worries. Several companies like Paytm, Bajaj Auto, and L&T are in focus due to ...
- Emcure eyes India growth, global deals amid strong demandEmcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in I...
- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian markets closed lower amid selling in financial, consumer and realty stocks, with Nifty and Sensex declining. Technical indicators si...
- Adani Ports, Tata Motors and Siemens Energy witness block deal action on MondayInstitutional investors injected over Rs 7,400 crore into Adani Ports and Special Economic Zone (APSEZ) on Monday through significant block...
- Mauritius-based entity sells Rs 289 crore worth shares in Emcure Pharmaceuticals via block deal; Norges Bank acquirerEmcure Pharmaceuticals saw a significant block deal where BC Investments IV Limited sold 18 lakh shares for Rs 289 crore to Norges Bank. Th...
- ‘Doing what I do best’: Namita Thapar shares new reel amid controversyEmcure Pharmaceuticals' Namita Thapar shared a health awareness video amid controversy over her namaz remarks. Meanwhile, Lenskart faced ba...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- 'I don’t care...': Namita Thapar reacts to online trolling over her video on health benefits of namazNamita Thapar has responded to online trolling over her video on the health benefits of namaz. Her comments come amid wider corporate contr...
- Narendra Solanki sees limited IT growth, bets on rural and pharma playsInvestors are becoming selective, focusing on earnings visibility and strong balance sheets. Opportunities are emerging in sectors like IT,...
- Cancer drug makers seek 50% price hike as platinum surge hits production viabilityLocal drug manufacturers are struggling to produce essential cancer medicines like carboplatin and cisplatin due to a significant surge in ...
- Emcure cuts semaglutide injection price by average 47%The starting dose price is cut by 55% to Rs 3,999 per month (four weekly doses). The innovator semaglutide is available in a once-weekly pe...
- Emcure slashes prices of weight management drug Poviztra by up to 55%Emcure Pharmaceuticals is making its weight management drug Poviztra more accessible. The price of the semaglutide injection will be cut by...
- Emcure, Sanofi sign distribution pact for oral anti-diabetic products in IndiaEmcure Pharmaceuticals and Sanofi India have announced a distribution agreement. Emcure will promote Sanofi India's oral anti-diabetic prod...
- Emcure Pharmaceuticals IPO: 10 things to know before subscribing to the issueEmcure Pharmaceuticals IPO is scheduled to open for subscription on July 3 and will close on July 5. The company aims to raise approximatel...
- Emcure and its subsidiary Gennova settle legal dispute with HDT Bio over mRNA technologyEmcure Pharmaceuticals and its subsidiary Gennova have resolved all legal disputes with US-based HDT Bio Corp. The parties have entered int...
- Roche, Emcure may end pact to make 2 blockbuster drugsEmcure is still the distributor for those two drugs in India. Roche had handed out the manufacturing and marketing of trastuzumab and ritux...
Load More
